Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes

Open access
Funk, Steven Daniel, Yurdagul, Arif, Orr, A. Wayne · 2012 · International Journal of Vascular Medicine

Abstract

A clear relationship between diabetes and cardiovascular disease has been established for decades. Despite this, the mechanisms by which diabetes contributes to plaque formation remain in question. Some of this confusion derives from studies in type 2 diabetics where multiple components of metabolic syndrome show proatherosclerotic effects independent of underlying diabetes. However, the hyperglycemia that defines the diabetic condition independently affects atherogenesis in cell culture systems, animal models, and human patients. Endothelial cell biology plays a central role in atherosclerotic plaque formation regulating vessel permeability, inflammation, and thrombosis. The current paper highlights the mechanisms by which hyperglycemia affects endothelial cell biology to promote plaque formation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2012/569654

Cites

Statistics

Figures

Figure 1 Stages of atherosclerotic plaque formation. Early apoB-containing lipoprotein accumulation and monocyte binding drive the early stages of plaque development forming fatty streaks in the vessel wall. While these processes continue in advanced atherosclerosis, monocyte cell death, smooth muscle recruitment, and matrix deposition are hallmarks of atheroma formation. Superficial plaque erosion and rupture of the smooth muscle-rich fibrotic cap cause plaque-associated thrombosis culminating in a clinical event.
Figure 1 Stages of atherosclerotic plaque formation. Early apoB-containing lipoprotein accumulation and monocyte binding drive the early stages of plaque development forming fatty streaks in the vessel wall. While these processes continue in advanced atherosclerosis, monocyte cell death, smooth muscle recruitment, and matrix deposition are hallmarks of atheroma formation. Superficial plaque erosion and rupture of the smooth muscle-rich fibrotic cap cause plaque-associated thrombosis culminating in a clinical event.CC BY · PubMed Central
Figure 2 Interplay between endothelial cell dysfunction and endothelial cell activation. (a) Cytokines and oxidized LDL stimulate endothelial cell permeability and NF-κB-dependent inflammatory gene expression. ROS appear to play a central role mediating both responses. (b) In addition to its vasodilatory properties, NO promotes barrier stability, limits inflammation, inhibits platelet aggregation, and limits SMC proliferation. Loss of these protective properties in endothelial cell dysfunction therefore perpetuates endothelial cell activation.
Figure 2 Interplay between endothelial cell dysfunction and endothelial cell activation. (a) Cytokines and oxidized LDL stimulate endothelial cell permeability and NF-κB-dependent inflammatory gene expression. ROS appear to play a central role mediating both responses. (b) In addition to its vasodilatory properties, NO promotes barrier stability, limits inflammation, inhibits platelet aggregation, and limits SMC proliferation. Loss of these protective properties in endothelial cell dysfunction therefore perpetuates endothelial cell activation.CC BY · PubMed Central
Figure 3 Hyperglycemia-induced endothelial dysfunction and activation. (a) Hyperglycemia induces metabolic dysfunction through mitochondrial production of superoxide, resulting in PARP activation and subsequent altered glycolytic flux to enhance diacylglycerol production (DAG), methylglyoxal production, and hexosamine and polyol pathway activity. (b) Hyperglycemia-induced oxidative stress is further enhanced by metabolic overproduction of DAG and decreases in NADH+/reduced glutathione (GSH), as well as stimulation of the RAGE receptor. Oxidative stress reduces protective mediators (NO bioavailability) and enhances inflammatory transcription factor (NF-κB) activation resulting in inflammatory gene expression and leukocyte recruitment.
Figure 3 Hyperglycemia-induced endothelial dysfunction and activation. (a) Hyperglycemia induces metabolic dysfunction through mitochondrial production of superoxide, resulting in PARP activation and subsequent altered glycolytic flux to enhance diacylglycerol production (DAG), methylglyoxal production, and hexosamine and polyol pathway activity. (b) Hyperglycemia-induced oxidative stress is further enhanced by metabolic overproduction of DAG and decreases in NADH+/reduced glutathione (GSH), as well as stimulation of the RAGE receptor. Oxidative stress reduces protective mediators (NO bioavailability) and enhances inflammatory transcription factor (NF-κB) activation resulting in inflammatory gene expression and leukocyte recruitment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 280 · Cited by 176

Research works printed but not linked: 10

  1. 2006, Handbook of Experimental Pharmacology, 135
  2. 1991, American Journal of Hypertension, 4, 260
  3. 1987, New England Journal of Medicine, 317, 836
  4. 1998, Cellular and Molecular Biology (Noisy-le-Grand), 44, 1139
  5. 2001, Diabetes and Metabolism, 27, 535
  6. 2008, Zhonghua Fu Chan Ke Za Zhi, 43, 746
  7. 2007, Behavioral Healthcare, 27, 22
  8. 2011, Journal of Endocrinological Investigation, 34, e343
  9. 1994, Research Communications in Chemical Pathology and Pharmacology, 84, 93
  10. 1993, American Journal of Physiology, 265, E783

Metadata

Authors
Funk, S. D., Yurdagul, A., & Orr, A. W.
Affiliations
Louisiana State University Health Sciences Center Shreveport (US)
Corresponding author
Orr, A. Wayne
Venue
International Journal of Vascular Medicine
Publisher
Wiley
Published
2012
Volume
2012
Pages
1-19
ISSN
  • 2090-2824 (ISSN-L)
  • 2090-2832
OpenAlex
W1969615558
Cited by
176
References
280
Citations by year
2026: 4 · 2025: 14 · 2024: 11 · 2023: 9 · 2022: 10 · 2021: 18 · 2020: 16 · 2019: 12 · 2018: 17 · 2017: 10 · 2016: 17 · 2015: 12 · 2014: 13 · 2013: 10 · 2012: 2
FWCI
7.93
Type
journal article
Language
en
Open access
Locations
  • International Journal of Vascular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
American Diabetes Association
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
hyperglycemia, endothelial dysfunction, atherosclerosis, type 1 diabetes, atherogenesis, endothelial cells, atherosclerotic plaque formation, diabetes and cardiovascular disease, metabolic syndrome, inflammation, thrombosis, vascular permeability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes. https://app.cochat.ai/papers/10.1155/2012/569654
The paper
Funk, S. D., Yurdagul, A., & Orr, A. W. (2012). Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes. International Journal of Vascular Medicine. https://doi.org/10.1155/2012/569654

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.